Press releases
- Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium
- Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
- Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
- Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
- Lineage Announces Changes to Board of Directors
- Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
- Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
- RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
- RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.90 |
---|---|
High | 0.975 |
Low | 0.90 |
Bid | 0.95 |
Offer | 1.00 |
Previous close | 0.90 |
Average volume | 2.34k |
---|---|
Shares outstanding | 188.82m |
Free float | 188.01m |
P/E (TTM) | -- |
Market cap | 190.71m USD |
EPS (TTM) | -0.1344 USD |
Data delayed at least 15 minutes, as of May 22 2024 18:31 BST.
More ▼